115 results about "Cinacalcet" patented technology

Processes for preparing cinacalcet are provided.

Provided is a process for preparing cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine.

The present invention is an oral solid pharmaceutical compositions for the treatment of kidney diseases and mineral bone disorder including a phosphate binder, a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, the invention further including a method for preparing the pharmaceutical compositions including the steps of granulating cinacalcet and / or sevelamer and / or vitamin D by one of a wet and a dry granulation process, each with at least one pharmaceutically acceptable excipient to form cinacalcet granules and / or sevelamer granules and / or vitamin D granules, mixing at least two of the cinacalcet granules, sevelamer granules and vitamin D granules to form a granules mixture and compressing the granules mixture to tablets or encapsulating the granules mixture into capsules or pulverizing the granules mixture into a dispersion powder.

The invention is directed to compositions comprising stable nanoparticulate cinacalcet or a salt thereof. The composition can exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions. The invention also encompasses methods of making and using such compositions.

The invention discloses a process for preparing Cinacalcet hydrochloride tablets or capsules and belongs to the technical field of medicinal preparations. The preparation process comprises performing dry-process granulation according to one formula; and tabletting or filling capsules by using three dosages according to a ratio. The in-vitro release of the Cinacalcet hydrochloride is characterized in that: 40 to 80 percent of Cinacalcet hydrochloride is released within 5 to 10 minutes; 80 to 90 percent of the Cinacalcet hydrochloride is released within 15 to 20 minutes; and 90 to 100 percent of Cinacalcet hydrochloride is released within 30 to 45 minutes. In the process, the procedures are simple and safety, the quality is controllable, the cost is low, and the production period is short. The process is suitable for large-scale industrial production.

Provided are crystalline forms of Cinacalet HCl and processes for their preparation.

The present invention discloses a cinacalcet hydrochloride preparation method, which comprises: 1, adopting 3-(trifluoromethyl) phenyl propionaldehyde and R-1-(1-naphthyl)ethylamine as raw materials, and carrying out a condensation reduction reaction in a mixing reaction solvent in the presence of sodium triacetoxyborohydride, 2, extracting the reaction product with water, a salt or an alkali aqueous solution to obtain a cinacalcet base organic phase solution, and 3, carrying out acidification salification on the obtained cinacalcet base organic phase solution with hydrochloric acid to obtain the cinacalcet hydrochloride, wherein one of components in the mixing reaction solvent is water. According to the present invention, the water-containing mixing solvent is adopted as the reaction medium, such that technical defects of solvent use during the sodium triacetoxyborohydride use process are overcome, the harsh condition that the reaction solvent requires a water-free treatment is avoided while reaction selectivity is increased, types of produced impurities and impurity content are substantially reduced, cost is reduced, and environment pollution is reduced.

Described are compositions of stable nanoparticulate cinacalcet or a salt thereof, and methods of making and using them. The compositions exhibit an improved dissolution rate, improved bioavailability, and reduced difference in absorption when administered orally under fed as compared to fasting conditions.

Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.

Methods for modulating serum phosphorus levels are described, wherein calcimimetic agents are administered to a subject in need thereof. In one embodiment, the compound is cinacalcet, and in other embodiments the compound is comprised of a contiguous sequence of subunits, X1—X2—X3—X4—X5—X6—X7, wherein the X1 subunit comprises a thiol-containing moiety and the distribution of charge on the X2-X7 subunits. The compound, when administered at selected times to a patient undergoing dialysis, lowers serum phosphorus levels, relative to pre-dosing levels, and achieves a sustained reduced level for a period of time after administration.